The attraction of chemokines as a target for specific anti-inflammatory therapy

Authors

  • James E Pease,

    1. Leukocyte Biology Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, South Kensington Campus, London SW7 2AZ
    Search for more papers by this author
  • Timothy J Williams

    Corresponding author
    1. Leukocyte Biology Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, South Kensington Campus, London SW7 2AZ
    Search for more papers by this author

Leukocyte Biology Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, South Kensington Campus, London SW7 2AZ. E-mail: tim.williams@imperial.ac.uk

Abstract

Since the identification of the first chemotactic cytokines 20 years ago, the field has mushroomed, with the discovery of approximately 40 ligands, which interact with 20 different cell surface receptors. At the time of writing this review, a PubMed trawl using the word ‘chemokine’ will recover over 28,000 manuscripts. In this article, we will give a short history of the discovery of chemokines and provide examples of the potential for therapeutic targeting of the chemokine network in inflammatory disease.

British Journal of Pharmacology (2006) 147, S212–S221. doi:10.1038/sj.bjp.0706475

Ancillary